Eli Lilly raises 2024 sales and profit outlook due to high demand for Zepbound and Mounjaro drugs.

Eli Lilly raised its annual outlook for sales and profit as the company ramps up production to meet soaring demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro. The company increased its 2024 guidance after Zepbound sales exceeded expectations, with revenue expected to be between $42.4 billion and $43.6 billion. Lilly's shares rose 5% on Tuesday following the announcement.